Shanghai Yinuo Pharmaceutical

Shanghai Yinuo Pharmaceutical is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics for oncology and inflammatory diseases. Headquartered in Shanghai's Zhangjiang Hi-Tech Park, the company utilizes a proprietary structure-based drug design platform to target challenging proteins within the RAS/MAPK signaling pathway. Its lead clinical candidate, YN-001, is a highly selective SHP2 inhibitor currently being evaluated in Phase 1 trials for the treatment of advanced solid tumors. Yinuo aims to address significant unmet medical needs by advancing a pipeline of precision medicines through both internal R&D and strategic global collaborations.